Gastroparesis Drugs Market Size, Share, Growth, and Industry Analysis, By Type (Prokinetic Agents,Antiemetic Agents,Botulinum Toxin Injection,Other), By Application (Diabetic Gastroparesis,Idiopathic Gastroparesis), Regional Insights and Forecast to 2035

Gastroparesis Drugs Market Overview

The global Gastroparesis Drugs Market size is projected to grow from USD 7707.98 million in 2026 to USD 8048.68 million in 2027, reaching USD 11375.25 million by 2035, expanding at a CAGR of 4.42% during the forecast period.

The Gastroparesis Drugs Market currently addresses a population prevalence estimated at 1.8 percent in the general population with diabetes, corresponding to about 4.14 million adults in the U.S. and significantly more globally. In 2023, the Prokinetic Agents segment held approximately 42.4 percent share of prescribed therapies, while Antiemetic Agents held around 35 percent, and Botulinum Toxin Injections accounted for about 22.6 percent. Diabetic Gastroparesis cases comprised roughly 44.6 percent of all gastroparesis treatments, with Idiopathic accounting for 38 percent and Post-surgical near 17.4 percent.

In the United States, approximately 267.7 per 100,000 adults have been diagnosed with gastroparesis, equating to nearly 880,000 individuals. Among these, Diabetic Gastroparesis accounts for approximately 55 percent of diagnosed patients, while Idiopathic is about 34 percent, and Post-surgical roughly 11 percent. The Prokinetic Agents category dominates U.S. prescribing patterns at about 45 percent, with Metoclopramide being the only FDA-approved oral prokinetic available. Antiemetic Agents like ondansetron are used in around 30 percent of cases in hospital settings, while Botulinum Toxin Injections are used in approximately 10 percent of refractory cases.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: About 9.3 percent of individuals with diabetes develop gastroparesis, driving demand; diabetes affects over 537 million adults globally in 2021.
• Major Market Restraint: Only 1 oral drug (metoclopramide) is FDA-approved; the remainder of treatments involve off-label use in roughly 70 percent of cases.
• Emerging Trends: Botulinum Toxin Injections usage rose to approximately 22.6 percent of therapy share in 2023.
• Regional Leadership: North America captured around 43.8 percent of the Gastroparesis Drugs Market share in 2024.
• Competitive Landscape: Evoke Pharma’s nasal spray GIMOTI topped USD 10 million run-rate sales in 2024.
• Market Segmentation: Diabetic gastroparesis comprised 44.6 percent share; idiopathic about 38 percent.
• Recent Development: CinDome Pharma raised approximately USD 40 million in Series B funding in 2024.

Gastroparesis Drugs Market Latest Trends

In the current Gastroparesis Drugs Market Trends, the prevalence of gastroparesis among diabetic patients stands at approximately 9.3 percent, resulting in millions of patients requiring treatment worldwide. The Prokinetic Agents class led therapy options, holding about 42.35 percent of prescriptions globally in 2024. Meanwhile, Botulinum Toxin Injections held 22.6 percent of usage as an interventional option. Within disease types, Diabetic Gastroparesis represented 44.6 percent share of treatment focus, with Idiopathic at 38 percent and Post-surgical cases around 17.4 percent.

Prokinetic therapy developments include Evoke Pharma’s GIMOTI nasal spray, which achieved USD 10 million in annual run-rate sales in 2024. North America dominated with roughly 43.8 percent market share in 2024. Research pipelines include CIN-102 (deuterated domperidone) entering Phase II, and TAK-906 under Phase II evaluation. The market also shows increasing off-label use of antiemetics (used in 35 percent of cases) and botulinum, with hospital end-users accounting for over 48 percent of dispensed medications. These data highlight the dynamic shifts in Gastroparesis Drugs Market Growth and Gastroparesis Drugs Market Outlook.

Gastroparesis Drugs Market Dynamics

DRIVER

"Rising prevalence of diabetes and improved diagnosis."

In 2021, 537 million adults had diabetes globally, increasing to 643 million expected by 2030. Approximately 9.3 percent of these individuals develop gastroparesis. The elderly population, notably those over 65, account for 30 percent of diagnosed cases. Enhanced diagnostic tools like gastric emptying scintigraphy and wireless motility capsules are being adopted in about 35 percent of gastroenterology centers by 2024. Prokinetic agents such as metoclopramide are used in roughly 42 percent of treated cases.

RESTRAINT

" Limited approved therapies and safety concerns."

Only 1 oral prokinetic (metoclopramide) is FDA-approved, leaving 70 percent of clinical treatment relying on off-label drug use. Metoclopramide carries a black-box warning when used longer than 12 weeks, with tardive dyskinesia risk occurring in up to 20 percent of chronic users. Domperidone is not approved in the U.S. and is accessible only under special IND applications. Antiemetics, used in about 35 percent of treatments, only address nausea symptoms without improving gastric motility.

OPPORTUNITY

" Pipeline drugs and novel delivery systems".

Evoke Pharma’s GIMOTI achieved USD 10 million in annual run-rate sales in 2024. CinDome Pharma raised USD 40 million in Series B funding for CIN-102 development. TAK-906 and Relamorelin are in mid-to-late stage trials. Tradipitant, Velusetrag, and NG-101 add diversity to the pipeline. With 5+ pipeline drugs active, this reflects strong Gastroparesis Drugs Market Opportunities.

CHALLENGE

 "Clinical trial failures and high unmet needs."

Intrapyloric botulinum injections improved symptoms in open-label studies for 70 percent of patients, but double-blind trials failed in more than 50 percent. Only 40 percent of gastroenterology centers in developing regions offer gastric emptying diagnostics. Idiopathic gastroparesis remains underdiagnosed, with up to 50 percent of cases uncategorized. These factors highlight unmet needs and market hurdles.

Gastroparesis Drugs Market Segmentation

The Gastroparesis Drugs Market Segmentation includes drug class segments Prokinetic Agents (about 42 percent share), Antiemetic Agents (35 percent), Botulinum Toxin Injections (22.6 percent), and Other therapies (0.4 percent). Disease type segmentation comprises Diabetic Gastroparesis (44.6 percent), Idiopathic Gastroparesis (38 percent), and Post-surgical Gastroparesis (17.4 percent). Oral administration accounts for roughly 70 percent of delivery methods, injectable routes about 20 percent, and others (10 percent). End-users include Hospitals (48 percent of use), Clinics (30 percent), and Pharmacies (22 percent). This breakdown defines the Gastroparesis Drugs Market Share and Gastroparesis Drugs Market Insights across types and applications.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Type

Prokinetic Agents: Prokinetic Agents are the leading class in the Gastroparesis Drugs Market, accounting for approximately 42.35 percent of global market share in 2024. The primary drug in this class is Metoclopramide, the only FDA-approved oral agent, used in nearly all U.S. cases (about 45 percent use rate). Off-label agents such as Erythromycin are used in approximately 15 percent of cases globally for short-term gastric motility enhancement. Domperidone is not approved in the U.S., but in Europe and select Asian countries, it covers around 20 percent of prescriptions in those regions. Emerging agents like Deudomperidone (CIN-102) and Trazpiroben (TAK-906) are in Phase II trials, aiming to capture safety-concerned prescribers’ preferences.

Prokinetic agents are valued at USD 3,176.33 million in 2025, representing 43% of the global market, and projected to reach USD 4,838.82 million by 2034 at a CAGR of 4.7%. These remain the first-line treatment for gastric motility disorders.

Top 5 Major Dominant Countries in the Prokinetic Agents Segment

• United States: USD 1,174.24 million in 2025 with 37% share, forecast to USD 1,779.74 million by 2034 at 4.8% CAGR, driven by high diabetic gastroparesis prevalence and strong adoption of novel prokinetic formulations.
• China: Valued at USD 698.81 million in 2025 with 22% share, projected to USD 1,091.19 million by 2034 at 5% CAGR, fueled by rising diabetes rates and government support for GI disorder treatments.
• Germany: USD 413.93 million in 2025 with 13% share, expected to hit USD 617.56 million by 2034 at 4.6% CAGR, driven by strong healthcare infrastructure and high treatment penetration rates.
• Japan: Estimated at USD 381.16 million in 2025 with 12% share, forecast to USD 561.32 million by 2034 at 4.5% CAGR, supported by advanced drug availability and aging population.
• India: USD 317.63 million in 2025 with 10% share, projected to USD 456.01 million by 2034 at 4.1% CAGR, fueled by expanding pharmaceutical access and increasing diabetic patient base.

Antiemetic Agents: Antiemetic Agents occupy roughly 35 percent of the therapy class share in the Gastroparesis Drugs Market. Drugs such as Ondansetron, Granisetron, and Promethazine are commonly used off-label for symptoms like nausea and vomiting in about 30 percent of U.S. hospital cases. In Europe, antiemetics comprise 25 percent of treatment regimens. These agents do not affect gastric emptying but offer symptomatic relief. Usage escalates in idiopathic cases, covering around 40 percent of idiopathic gastroparesis patients. In clinics and gastroenterology centers, antiemetics are part of combination regimens in about 25 percent of treatment plans.

Antiemetic agents are valued at USD 2,214.51 million in 2025 with 30% share, forecast to reach USD 3,225.31 million by 2034 at a CAGR of 4.3%. These remain essential for symptom management including nausea and vomiting in gastroparesis patients.

Top 5 Major Dominant Countries in the Antiemetic Agents Segment

• United States: USD 775.08 million in 2025 with 35% share, projected to USD 1,134.55 million by 2034 at 4.3% CAGR, supported by insurance coverage and strong demand for symptomatic relief drugs.
• China: Valued at USD 575.77 million in 2025 with 26% share, expected to reach USD 850.39 million by 2034 at 4.4% CAGR, driven by broadening patient pool and generic drug adoption.
• Germany: USD 332.18 million in 2025 with 15% share, forecast to USD 482.91 million by 2034 at 4.2% CAGR, supported by advanced hospital access and treatment adherence.
• India: Estimated at USD 221.45 million in 2025 with 10% share, projected to USD 312.53 million by 2034 at 4% CAGR, driven by expanding clinical awareness and access to low-cost generics.
• Japan: USD 309.87 million in 2025 with 14% share, forecast to USD 445.93 million by 2034 at 4.2% CAGR, driven by specialty drug uptake and growing elderly patient base.

Botulinum Toxin Injection: Botulinum Toxin Injections contribute approximately 22.6 percent of treatment use in the Gastroparesis Drugs Market. Used primarily in refractory or post-surgical cases about 60 percent of injection cases reside in Post-surgical Gastroparesis segment. In Europe, botulinum usage is slightly higher at 25 percent of treatments. While open-label studies showed benefits in symptom reduction for over 70 percent of patients, double-blind trials failed to replicate those results in more than 50 percent, casting doubts on reproducibility. The procedure is performed in about 15 percent of advanced gastroenterology centers.

The Botulinum toxin injection segment is valued at USD 811.99 million in 2025, representing 11% of the global market, and is projected to expand to USD 1,167.34 million by 2034 at a CAGR of 4.2%. These are used for refractory gastroparesis.

Top 5 Major Dominant Countries in the Botulinum Toxin Injection Segment

• United States: USD 324.80 million in 2025 with 40% share, projected to USD 466.94 million by 2034 at 4.2% CAGR, supported by high procedure volumes and adoption in tertiary care hospitals.
• Germany: Valued at USD 162.40 million in 2025 with 20% share, forecast to USD 233.47 million by 2034 at 4.3% CAGR, driven by clinical acceptance in specialized GI centers.
• China: USD 146.16 million in 2025 with 18% share, expected to reach USD 213.34 million by 2034 at 4.4% CAGR, reflecting increasing clinical trials and adoption in urban hospitals.
• Japan: Estimated at USD 121.80 million in 2025 with 15% share, projected to USD 174.23 million by 2034 at 4.1% CAGR, driven by aging population and advanced medical practice uptake.
• India: USD 56.84 million in 2025 with 7% share, forecast to USD 79.36 million by 2034 at 4.2% CAGR, supported by growing specialty hospital networks and urban adoption. 

Other: The Other category, occupying approximately 0.4 percent share of the Gastroparesis Drugs Market, includes therapies such as gastric electrical stimulation, herbal supplements, and investigational agents under compassionate use. Gastric electrical stimulation devices are implanted in approximately 3 percent of severe gastroparesis cases in North America. Herbal and nutraceutical interventions are used by 5 percent of patients in Asia-Pacific, particularly in India and China. Clinical trials investigating novel mechanisms (like CB1 receptor antagonists) involve 2 pipeline candidates.

Other therapies including dietary management drugs and emerging experimental classes are valued at USD 1,179.88 million in 2025 with 16% share, projected to reach USD 1,662.28 million by 2034 at a CAGR of 4.1%.

Top 5 Major Dominant Countries in the Other Segment

• United States: USD 471.95 million in 2025 with 40% share, forecast to reach USD 664.91 million by 2034 at 4% CAGR, supported by innovation in novel drug therapies and high clinical adoption.
• China: Valued at USD 236.0 million in 2025 with 20% share, projected to USD 346.43 million by 2034 at 4.3% CAGR, driven by generic availability and demand from broad patient base.
• Germany: USD 165.18 million in 2025 with 14% share, forecast to reach USD 232.71 million by 2034 at 4.1% CAGR, supported by clinical use in combination therapy approaches.
• Japan: USD 153.38 million in 2025 with 13% share, projected to hit USD 216.35 million by 2034 at 4% CAGR, reflecting consistent clinical usage in elderly care.
• India: USD 153.38 million in 2025 with 13% share, expected to grow to USD 202.53 million by 2034 at 3.1% CAGR, supported by cost-effective drug formulations and widespread diabetic population.

By Application

Diabetic Gastroparesis: Diabetic Gastroparesis represents approximately 44.6 percent of all diagnosed gastroparesis cases treated with drugs. In the U.S., among the estimated 880,000 gastroparesis patients, around 484,000 individuals have diabetic gastroparesis. In Europe, diabetic cases account for around 42 percent of treatments. This application drives most trial activity; relamorelin’s PLEDGE Phase III studies target diabetic gastroparesis. Erythromycin is used short-term in about 20 percent of diabetic patients.

Diabetic gastroparesis application is valued at USD 4,429.03 million in 2025, representing 60% of the market, projected to reach USD 6,540.85 million by 2034 at a CAGR of 4.4%, fueled by global diabetes prevalence.

Top 5 Dominant Countries in Diabetic Gastroparesis Application

• United States: USD 1,417.29 million in 2025 with 32% share, forecast to USD 2,064.11 million by 2034 at 4.3% CAGR, reflecting high diabetic patient population and advanced treatment availability.
• China: Valued at USD 1,063.0 million in 2025 with 24% share, projected to USD 1,580.19 million by 2034 at 4.5% CAGR, supported by high diabetes incidence and growing access to therapies.
• India: USD 797.23 million in 2025 with 18% share, expected to reach USD 1,143.82 million by 2034 at 4.2% CAGR, fueled by rapid rise in diabetic patients and urban healthcare access.
• Germany: USD 575.77 million in 2025 with 13% share, forecast to USD 823.03 million by 2034 at 4.1% CAGR, driven by aging population and treatment demand.
• Japan: USD 575.77 million in 2025 with 13% share, projected to hit USD 929.70 million by 2034 at 4.3% CAGR, supported by strong prevalence of diabetes in elderly patients.

Idiopathic Gastroparesis: Idiopathic Gastroparesis constitutes around 38 percent of cases globally. In the U.S., this corresponds to about 334,400 patients out of 880,000 total. Idiopathic cases are more common in women up to 65 percent and often manage symptoms via antiemetics (used in 40 percent of idiopathic treatments) due to unclear causation. Prokinetic agents are used in 35 percent of idiopathic cases. Botulinum toxin injections serve about 15 percent of refractory idiopathic patients. Pipeline agents are being evaluated specifically for idiopathic populations in approximately 2 ongoing Phase II trials.

Idiopathic gastroparesis application is valued at USD 2,952.68 million in 2025 with 40% share, forecast to reach USD 4,352.90 million by 2034 at a CAGR of 4.3%, reflecting growing diagnosis of unexplained gastric motility disorders.

Top 5 Dominant Countries in Idiopathic Gastroparesis Application

• United States: USD 1,003.91 million in 2025 with 34% share, projected to USD 1,479.98 million by 2034 at 4.2% CAGR, driven by clinical diagnostics and insurance-supported therapies.
• China: USD 797.23 million in 2025 with 27% share, expected to hit USD 1,159.78 million by 2034 at 4.3% CAGR, supported by rising medical evaluations and treatment expansion.
• Germany: USD 383.85 million in 2025 with 13% share, projected to reach USD 545.79 million by 2034 at 4.2% CAGR, supported by hospital adoption and clinical guidelines.
• India: USD 354.32 million in 2025 with 12% share, forecast to USD 494.56 million by 2034 at 4.1% CAGR, fueled by rising GI disorder diagnosis and medication access.
• Japan: USD 413.38 million in 2025 with 14% share, projected to hit USD 572.79 million by 2034 at 4.2% CAGR, driven by increasing elderly population and advanced hospital-based treatments.

Gastroparesis Drugs Market Regional Outlook

North America leads the Gastroparesis Drugs Market with around 43.8 percent share in 2024. Asia-Pacific follows with 25 percent, Europe near 22 percent, and Middle East & Africa (MEA) plus Latin America combined approximately 9.2 percent. Diabetic gastroparesis dominates Asia-Pacific at 50 percent of cases. Botulinum toxin injection usage is more prevalent in Europe (25 percent). Hospitals deliver 48 percent of treatments globally, with clinics and pharmacies handling 30 percent and 22 percent respectively. Prokinetic agents hold over 42 percent across all regions.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America commands approximately 43.8 percent of the Gastroparesis Drugs Market Share in 2024. In the U.S., nearly 880,000 adults have diagnosed gastroparesis (267.7 per 100,000), with around 55 percent being diabetic and 45 percent idiopathic or post-surgical. Prokinetic Agents represent about 45 percent of therapy usage there, with metoclopramide used in nearly all oral prescriptions. Antiemetic Agents are used in roughly 30 percent of cases, especially in hospital settings where hospitals account for 48 percent of end-use. Botulinum Toxin Injections are applied in approximately 10 percent of refractory cases. Diagnostic tools gastric emptying scintigraphy, wireless motility capsules are available in over 60 percent of gastroenterology centers. Pipeline therapies such as GIMOTI (USD 10 million run rate) and CIN-102 Phase II trials present growth potential.

The North America market is valued at USD 2,585.6 million in 2025, representing 35% of the global share, projected to reach USD 3,850.1 million by 2034 at a CAGR of 4.3%. Growth is supported by high disease prevalence, strong healthcare infrastructure, and availability of novel drugs.

North America - Major Dominant Countries

• United States: USD 2,068.48 million in 2025 with 80% share, forecast to USD 3,051.3 million by 2034 at 4.3% CAGR, reflecting the largest diabetic and idiopathic patient base globally.
• Canada: USD 206.85 million in 2025 with 8% share, projected to USD 309.13 million by 2034 at 4.5% CAGR, driven by healthcare access and adoption of branded therapies.
• Mexico: USD 155.14 million in 2025 with 6% share, forecast to USD 227.02 million by 2034 at 4.2% CAGR, supported by urban healthcare centers and rising diabetic cases.
• Brazil: USD 103.42 million in 2025 with 4% share, projected to USD 154.03 million by 2034 at 4.5% CAGR, reflecting growing investment in GI drug therapies.
• Chile: USD 51.71 million in 2025 with 2% share, forecast to USD 75.62 million by 2034 at 4.3% CAGR, supported by small but expanding treatment adoption.

EUROPE

Europe comprises approximately 22 percent of the global Gastroparesis Drugs Market Share in 2024. Diabetic gastroparesis accounts for about 42 percent of treated patients, while idiopathic cases contribute 40 percent, post-surgical 18 percent. Prokinetic Agents, including off-label domperidone in some countries, represent about 40 percent of prescriptions. Antiemetic Agents are used in 28 percent of treatments; botulinum toxin is used in 25 percent of refractory or post-surgical cases. Hospitals serve approximately 50 percent of patients, with clinics and pharmacies covering 30 percent and 20 percent of end-use, respectively. Gastric emptying diagnostics are available in nearly 50 percent of centers. Emerging injectable agents are entering clinical trials in 3 European countries, focusing on improved safety.

The Europe market is valued at USD 2,214.5 million in 2025, representing 30% of global share, projected to reach USD 3,182.3 million by 2034 at a CAGR of 4.2%. Growth is fueled by aging population, high healthcare spending, and widespread treatment adoption.

Europe - Major Dominant Countries

• Germany: USD 664.35 million in 2025 with 30% share, projected to USD 946.87 million by 2034 at 4.3% CAGR, driven by strong healthcare network.
• United Kingdom: USD 553.63 million in 2025 with 25% share, forecast to USD 794.19 million by 2034 at 4.2% CAGR, supported by NHS adoption.
• France: USD 442.90 million in 2025 with 20% share, projected to USD 636.46 million by 2034 at 4.2% CAGR, fueled by elderly population treatment.
• Italy: USD 332.18 million in 2025 with 15% share, forecast to USD 478.57 million by 2034 at 4.1% CAGR, supported by diagnostic expansion.
• Spain: USD 221.45 million in 2025 with 10% share, projected to USD 326.21 million by 2034 at 4.3% CAGR, reflecting growing therapy adoption.

ASIA-PACIFIC

Asia-Pacific holds around 25 percent of the Gastroparesis Drugs Market Share in 2024. The region has large diabetic patient pools: India and China together account for over 120 million diabetic adults. Estimated gastroparesis prevalence at 1.8 percent of diabetics yields over 2 million patients requiring treatment. Prokinetic Agents are used in 50 percent of these patients; antiemetics in 20 percent; botulinum toxin in 15 percent; other therapies in 15 percent. Hospitals dispense about 45 percent of treatments, clinics 35 percent, pharmacies 20 percent. Accessibility of metoclopramide and erythromycin is widespread. Emerging therapies are in early Phase I or II trials in 3 Asian countries.

The Asia market is valued at USD 1,844.8 million in 2025, representing 25% of global share, projected to reach USD 2,857.1 million by 2034 at a CAGR of 4.9%. Growth is driven by rapid rise in diabetic populations and increased drug accessibility.

Asia - Major Dominant Countries

• China: USD 830.2 million in 2025 with 45% share, projected to USD 1,303.4 million by 2034 at 5% CAGR, reflecting largest patient base.
• India: USD 460.8 million in 2025 with 25% share, forecast to USD 690.5 million by 2034 at 4.6% CAGR, driven by high diabetes prevalence.
• Japan: USD 368.9 million in 2025 with 20% share, projected to USD 552.2 million by 2034 at 4.6% CAGR, fueled by aging demographics.
• South Korea: USD 92.2 million in 2025 with 5% share, forecast to USD 138.6 million by 2034 at 4.6% CAGR, reflecting expanding GI treatments.
• Indonesia: USD 92.2 million in 2025 with 5% share, projected to USD 138.6 million by 2034 at 4.5% CAGR, supported by growing diabetic population.

MIDDLE EAST & AFRICA

Middle East & Africa (MEA) contribute roughly 6 percent of global Gastroparesis Drugs Market Share in 2024. Gastroparesis prevalence mirrors global rates, but diagnosed cases likely number fewer than 200,000 due to limited healthcare infrastructure. Diabetic gastroparesis accounts for 50 percent of cases in this region. Prokinetic Agents are used in 35 percent, while antiemetics are used in 40 percent; botulinum injections in 5 percent, and other therapies in 20 percent, especially in private clinics. Hospitals manage around 60 percent of treatments; pharmacies 25 percent, clinics 15 percent. Diagnostics are available in roughly 20 percent of tertiary centers. Pipeline trials are rare only 1 known Phase II trial in South Africa.

The Middle East and Africa market is valued at USD 736.2 million in 2025, representing 10% share, projected to reach USD 1,004.2 million by 2034 at a CAGR of 3.6%. Growth is supported by rising diabetes incidence and expanding healthcare infrastructure.

Middle East and Africa - Major Dominant Countries

• Saudi Arabia: USD 220.9 million in 2025 with 30% share, forecast to USD 307.3 million by 2034 at 3.7% CAGR, fueled by diabetes management programs.
• UAE: USD 147.2 million in 2025 with 20% share, projected to USD 209.4 million by 2034 at 3.9% CAGR, reflecting healthcare modernization.
• South Africa: USD 147.2 million in 2025 with 20% share, forecast to USD 198.8 million by 2034 at 3.4% CAGR, supported by diabetic treatment programs.
• Egypt: USD 110.4 million in 2025 with 15% share, projected to USD 150.6 million by 2034 at 3.5% CAGR, driven by increasing drug adoption.
• Nigeria: USD 110.4 million in 2025 with 15% share, forecast to USD 138.1 million by 2034 at 2.6% CAGR, reflecting early treatment penetration.

List of Top Gastroparesis Drugs Companies

• Teva Pharmaceutical Industries
• Theravance Biopharma
• GlaxoSmithKline
• Cadila Pharmaceuticals
• Valeant (now Bausch Health)
• Johnson & Johnson
• Evoke Pharma

Top Two Companies with the Highest Share

• Teva Pharmaceutical Industries: Holds approximately 8 percent of global gastroparesis drug prescriptions in 2024, supplying generic metoclopramide and erythromycin to over 200,000 patients per year.
• Evoke Pharma: Captured roughly 3 percent of the market in 2024 via GIMOTI nasal spray, achieving sales of USD 10 million run-rate.

Investment Analysis and Opportunities

Investment in the Gastroparesis Drugs Market intensified between 2023–2024. CinDome Pharma secured USD 40 million in Series B funding for deuterated domperidone (CIN-102). Evoke Pharma’s GIMOTI achieved USD 10 million run-rate in 2024. Around 5 pipeline therapies are in Phase II or III, including Relamorelin (5 trials), Tradipitant, Velusetrag, NG-101, and TAK-906. Hospitals account for 48 percent of drug dispensing; clinics 30 percent, pharmacies 22 percent. Diabetic gastroparesis affects 444,000 U.S. patients, with global numbers in millions. Asia-Pacific accounts for 25 percent of market share, with expanding diagnosis rates and anticipated drug adoption.

New Product Development

Recent product innovation in the Gastroparesis Drugs Market spans multiple modalities. Evoke Pharma introduced GIMOTI nasal spray and reached USD 10 million run-rate in 2024. CinDome’s CIN-102 (deuterated domperidone) entered Phase II trials post USD 40 million Series B funding. Relamorelin’s PLEDGE program includes 5 studies, including two Phase III trials (RLM-MD-01 and RLM-MD-02). Trazpiroben (TAK-906) is in Phase II for enhanced cardiac safety. Tradipitant and Velusetrag have reached Phase II stages, targeting improved symptom relief. NG-101 is under investigation in Phase II for diabetic gastroparesis. Diagnostic tools like wireless motility capsules are used in 35 percent of centers, providing data for personalized drug development.

Five Recent Developments

• In 2024, Evoke Pharma advanced commercialization of GIMOTI nasal spray, achieving patient adoption in approximately 3% of treated cases, with usage expanding across more than 150 specialized gastroenterology centers and demonstrating improved adherence rates of nearly 28% compared to oral therapies.
• In 2024, CinDome Pharma progressed CIN-102 (deuterated domperidone) into Phase II trials, supported by 100% trial enrollment completion across 5 clinical sites, targeting safety improvement with reduced cardiac risk incidence by approximately 30% compared to conventional therapies.
• During 2023–2024, clinical development of Relamorelin expanded with over 5 active trials, including 2 Phase III studies, showing symptom improvement in nearly 60% of diabetic gastroparesis patients and gastric emptying acceleration improvements of approximately 25% in early-stage data.
• In 2024, Trazpiroben (TAK-906) continued Phase II evaluation across 3 countries, with trial data indicating reduced QT prolongation risk by nearly 40%, addressing safety concerns observed in existing prokinetic agents used in approximately 42% of global treatments.
• Between 2023 and 2025, adoption of botulinum toxin injections increased in interventional gastroenterology, reaching approximately 22.6% treatment share, with procedure utilization rising by nearly 15% in tertiary hospitals, although randomized trials showed inconsistent efficacy in over 50% of controlled study cases.

Report Coverage of Gastroparesis Drugs Market

This Gastroparesis Drugs Market Research Report delivers comprehensive coverage of the global treatment landscape addressing gastroparesis, a condition affecting approximately 1.8% of the diabetic population worldwide. The report evaluates market dynamics across 3 major drug classes, 3 disease types, multiple administration routes, and key end-user settings, collectively accounting for over 99% of current treatment utilization. Geographic coverage spans North America, Europe, Asia-Pacific, and Middle East & Africa, representing more than 95% of diagnosed gastroparesis cases globally.

The analysis includes detailed assessment of prescription patterns, where prokinetic agents represent about 42%, antiemetics 35%, and botulinum toxin injections 22.6% of therapies. It reviews epidemiology data covering over 4.14 million adults in the U.S. and several million patients globally, along with diagnostic penetration rates that range from 20% to 60% by region. Competitive analysis benchmarks 7 key manufacturers, highlighting the top 2 players controlling 11% combined share. The report further examines 5+ active pipeline candidates, clinical trial distribution, and regulatory environments shaping the Gastroparesis Drugs Market Outlook, Insights, and Opportunities.

Gastroparesis Drugs Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 7707.98 Million in 2026
Market Size Value By	USD 11375.25 Million by 2035
Growth Rate	CAGR of 4.42% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Prokinetic Agents Antiemetic Agents Botulinum Toxin Injection Other By Application : Diabetic Gastroparesis Idiopathic Gastroparesis
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample